検索 条件検索
wx_img
Inquiry Form
  1. Home
  2. NX-5948

NX-5948

Nurix announced the presentation of the first findings of clinical responses in the brain for NX-5948. NX-5948 is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.

4-(1,3-dioxolan-2-yl)piperidine
4-(1,3-dioxolan-2-yl)piperidine
CM743777
202062-80-4
Methyl 5-fluoropyridine-2-carboxylate
Methyl 5-fluoropyridine-2-carboxylate
CM176763
107504-07-4
(S)-3-Amino-piperidine-2,6-dione hydrochloride
(S)-3-Amino-piperidine-2,6-dione hydrochloride
CM434963
25181-50-4
(R)-1-Boc-3-Aminopiperidine
(R)-1-Boc-3-Aminopiperidine
CM101966
188111-79-7
tert-butyl (3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidine-1-carboxylate
tert-butyl (3R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidine-1-carboxylate
CM1046410
1791402-88-4
3,5-dichloropyrazine-2-carbonitrile
3,5-dichloropyrazine-2-carbonitrile
CM102418
313339-92-3
1-Boc-4-(4-Aminophenyl)piperidine
1-Boc-4-(4-Aminophenyl)piperidine
CM180999
170011-57-1